Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 10 of 20
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Viral Hepatitis and Liver Diseases in Mongolia
    (Jaypee Brothers Medical Publishing, 2017-06-01) ;
    Uugantsetseg, G
    ;
    Munkh-Orshikh, D
    ;
    Naranzul, N
    ;
    Badamjav, S
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
    (Springer Science and Business Media LLC, 2019-02)
    Lee, Hye Won
    ;
    Kim, Seung Up
    ;
    ;
    Park, Jun Yong
    ;
    Routine nucleos(t)ide analogs (NUCs) have not yet been recommended for patients with immune-tolerant (IT) phase in chronic hepatitis B virus (HBV) infection. We aimed to evaluate prognosis of patients in untreated IT-phase (UIT group), compared to those in immune-active phase who achieved virological response by NUCs according to guidelines (VR group). Between 2006 and 2012, patients in UIT or VR groups were included. Cumulative risks of HCC and liver-related events (LREs) development were assessed. Furthermore, propensity-score was calculated based upon age, gender, diabetes and liver stiffness. UIT group (n = 126) showed younger age, lower proportion of male gender and lower LS than VR group (n = 641). UIT group had similar 10-year cumulative risks of HCC (2.7% vs. 2.9%, p = 0.704) and LRE (4.6% vs. 6.1%, p = 0.903) development, compared to VR group. When we re-defined UIT group by the lower ALT cut-offs, 10-year cumulative risks of HCC and LRE development were 2.9% and 4.8%, respectively. Using propensity-score matching and inverse probability treatment weighting analysis, similar results were reproduced. UIT group consistently had similar prognosis compared to VR group. Therefore, further large-scale prospective studies in order to verify rationales of routine NUCs in UIT group are still required.
    Scopus© Citations 31
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Hepatitis B e antigen‐negative mutations in the precore and core promoter regions in Korean patients
    (Wiley, 2009-04)
    Choi, Jong Won
    ;
    Ahn, Sang Hoon
    ;
    Park, Jun Yong
    ;
    Chang, Hye Young
    ;
    Kim, Ja Kyung
    Scopus© Citations 19
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
    (The Korean Association for the Study of the Liver, 2013)
    Park, Mi Sung
    ;
    Kim, Beom Kyung
    ;
    Kim, Kyung Sik
    ;
    Kim, Ja Kyung
    ;
    Kim, Seung Up
    Scopus© Citations 10
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Scopus© Citations 31
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Current situation of hepatocellular carcinoma in Mongolia
    (S. Karger AG, 2011) ; ;
    Bat-Ireedui, Purevbaatar
    ;
    Han, Kwang-Hyub
    Mongolia is one of the nations with the highest incidence of hepatocellular carcinoma (HCC) worldwide; it occurs in 54.1 cases per 100,000 people each year and is attributable to a high prevalence of chronic viral hepatitis. Although universal vaccination for hepatitis B virus has been implemented and sterilization of medical devices is being improved, the prevalence of chronic hepatitis B and C is still over 10%. Primary prevention of HCC is currently hard to achieve because of a limited availability of antiviral therapy. A significant proportion of HCC patients in Mongolia is diagnosed in the advanced stage, and this is due to the lack of a surveillance system using ultrasound and serum α-fetoprotein for early detection. Moreover, the resources for high resolution imaging such as computed tomography are absolutely insufficient in number, and the treatment modalities physicians can choose are largely restricted. Considering that HCC is the most prevalent malignancy in Mongolia, a systematic approach to prevention, early detection, and effective treatment is urgently required.
    Scopus© Citations 13
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis
    (Springer Science and Business Media LLC, 2019-12)
    Kim, David Sooik
    ;
    Lim, Tae Seop
    ;
    Jeon, Mi Young
    ;
    Kim, Beom Kyung
    ;
    Park, Jun Yong
    OBJECTIVES: Transarterial chemoembolization (TACE) improves the survival of patients with hepatocellular carcinoma (HCC); however, TACE treatment outcomes of patients with treatment-naïve HCC (TN-HCC) and those with recurrent HCC after curative resection (R-HCC) have not yet been compared. METHODS: We recruited 448 patients with TN-HCC, and 275 patients with R-HCC treated with TACE as first-line anti-cancer treatment. RESULTS: At first TACE, patients with TN-HCC showed a significantly lower proportion of male gender (74.9% vs. 84.3%), higher proportion of liver cirrhosis (61.9% vs. 49.3%), higher aspartate aminotransferase (median 48 vs. 31 IU/L), alanine aminotransferase (median 38 vs. 26 IU/L), alpha-fetoprotein (AFP) (median 96.6 vs. 7.7 ng/mL), and total bilirubin (mean 1.0 vs. 0.8 mg/dL) levels, longer prothrombin time (median 1.05 vs. 1.01 international normalized ratio), higher tumor number (mean 2.1 vs. 1.7), larger tumor size (median 3.1 vs. 1.6 cm), and lower proportion of Barcelona Clinic Liver Cancer stage 0-A (55.6% vs. 71.9%) than patients with R-HCC (all P < 0.05). Multivariate analysis showed that TACE for TN-HCC (vs. R-HCC) was an independent predictor of mortality (hazard ratio, 1.328; P = 0.024) with AFP level and tumor number (all P < 0.05). However, treatment outcomes between TN-HCC and R-HCC became statistically similar after propensity score-matched (PSM) analysis using liver cirrhosis, tumor size, and multiple tumors (P < 0.05). CONCLUSIONS: Based on the similar TACE treatment outcomes observed with the PSM analysis, the current TACE treatment guideline for patients with TN-HCC might similarly be applied for patients with R-HCC.
    Scopus© Citations 9
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus‐related advanced hepatocellular carcinoma
    (Wiley, 2012-09)
    Shin, Hye Sun
    ;
    Kim, Seung Up
    ;
    Park, Jun Yong
    ;
    ;
    Han, Kwang‐Hyub
    Scopus© Citations 16
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B
    (Elsevier BV, 2016-11)
    Kim, Hye Soo
    ;
    Kim, Beom Kyung
    ;
    Kim, Seung Up
    ;
    Park, Jun Yong
    ;
    BACKGROUND & AIMS: We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. METHODS: We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. RESULTS: Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P < .05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P > .05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P > .05). CONCLUSIONS: In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.
    Scopus© Citations 38
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study
    (Springer Science and Business Media LLC, 2012-10) ; ;
    Nymadawa, Pagbajabyn
    ;
    Kim, Seung Up
    ;
    Han, Kwang-Hyub
    Scopus© Citations 11